Search results for " Staging"

showing 10 items of 717 documents

VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced es…

2014

Abstract Background Combination of fluoropyrimidines and a platinum derivative are currently standards for systemic chemotherapy in advanced adenocarcinoma of the stomach and gastroesophageal junction (GEJ). Nevertheless, individual likelihood for response to these therapeutic regimes remains uncertain. Even more, no predictive markers are available to determine which patients may benefit more from oxaliplatin versus cisplatin or vice versa. The new invasion and stem cell markers VEGFR-3 and CXCR4 have been linked prognostically with more aggressive esophagogastric cancer types. Thus, we aimed to assess correlations of VEGFR-3 and CXCR4 expression levels with clinical outcome in a randomize…

OncologyMaleCancer ResearchOrganoplatinum Compoundsmedicine.medical_treatmentLeucovorinSurgical oncologyAntineoplastic Combined Chemotherapy ProtocolsAged 80 and overeducation.field_of_studyAdvanced esophagogastric cancerMiddle AgedPrognosisImmunohistochemistryOxaliplatinTreatment OutcomeOncologyFluorouracilAdenocarcinomaFemaleEsophagogastric JunctionFluorouracilmedicine.drugResearch ArticleAdultmedicine.medical_specialtyReceptors CXCR4FLOFLPPopulationStomach NeoplasmsInternal medicinemedicineGeneticsHumanseducationSurvival analysisAgedNeoplasm StagingCisplatinCXCR4Chemotherapybusiness.industrymedicine.diseaseVascular Endothelial Growth Factor Receptor-3OxaliplatinVEGFR-3CisplatinbusinessBiomarkersBMC Cancer
researchProduct

A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients

2011

<i>Background:</i> This phase II trial was conducted to determine the activity and safety of the combination of fixed-dose rate (FDR) gemcitabine and capecitabine in metastatic biliary tract cancer (BTC) patients. <i>Methods:</i> Patients with unresectable BTC who had pathologically confirmed adenocarcinoma, no prior chemotherapy, Eastern Cooperative Oncology Group (ECOG) performance status ≤1 and measurable disease were enrolled. Treatment consisted of FDR gemcitabine at 800 mg/m<sup>2</sup> on days 1 and 8 every 21 days with capecitabine administered orally b.i.d. in equal doses (650 mg/m<sup>2</sup> b.i.d.) for 14 days (28 doses). <i>…

OncologyMaleCancer Researchmedicine.medical_specialtyDisease free survivalSettore MED/06 - Oncologia MedicaDeoxycytidineDisease-Free SurvivalCapecitabineBiliary tract cancer; Capecitabine; Fixed-dose rate; GemcitabineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisCapecitabineAgedNeoplasm StagingBiliary tract cancerFixed-dose ratebusiness.industryGeneral MedicineFixed dose rateMiddle AgedGemcitabineGemcitabineClinical trialBiliary Tract NeoplasmsOncologyBiliary tract cancerNeoplasm stagingFemaleFluorouracilbusinessmedicine.drug
researchProduct

Multi-state relative survival modelling of colorectal cancer progression and mortality.

2015

Abstract Accurate identification of factors associated with progression of colorectal cancer remains a challenge. In particular, it is unclear which statistical methods are most suitable to separate the effects of putative prognostic factors on cancer progression vs cancer-specific and other cause mortality. To address these challenges, we analyzed 10 year follow-up data for patients who underwent curative surgery for colorectal cancer in 1985–2000. Separate analyses were performed in two French cancer registries. Results of three multivariable models were compared: Cox model with recurrence as a time-dependent variable, and two multi-state models, which separated prognostic factor effects …

OncologyMaleCancer Researchmedicine.medical_specialtyEpidemiologyColorectal cancer01 natural sciencesCancer recurrence010104 statistics & probability03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansRegistries0101 mathematicsStage (cooking)AgedNeoplasm StagingModels StatisticalMulti stateRelative survivalbusiness.industryProportional hazards modelCancermedicine.diseasePrognosis3. Good healthSurgerySurvival RateOncology030220 oncology & carcinogenesisCurative surgeryDisease ProgressionFemaleNeoplasm Recurrence LocalbusinessColorectal NeoplasmsCancer epidemiology
researchProduct

Metabolic classification of human rectal adenocarcinomas: a novel guideline for clinical oncologists?

2003

Based on previous findings in SCC of the human uterine cervix and of the head and neck, metastasis- and survival-related metabolic classification was performed in human rectal adenocarcinomas. Such a characterization is suggested as basis of a novel clinical guideline for an appropriate therapy of epithelium-derived malignancies.Tissue concentrations of ATP, glucose, and lactate in viable tumor regions of 33 pretherapeutically taken cryobiopsies from 24 patients were measured at a microscopic level using the technique of imaging bioluminescence.In metastatic carcinomas, lactate levels were significantly higher (mean+/-SD: 13.4+/-3.8 vs 6.9+/-2.5 micro mol/g, P = 0.0046) and glucose levels s…

OncologyMaleCancer Researchmedicine.medical_specialtyPathologyBiopsyRectumAdenocarcinomaMedical OncologyMetastasisText miningAdenosine TriphosphateInternal medicineBiopsymedicineHumansLactic AcidSurvival analysisAgedNeoplasm StagingAged 80 and overHematologymedicine.diagnostic_testbusiness.industryRectal NeoplasmsGeneral MedicineGuidelineMiddle Agedmedicine.diseasePrognosisSurvival Analysismedicine.anatomical_structureOncologyLuminescent MeasurementsPractice Guidelines as TopicAdenocarcinomaFemalebusinessJournal of cancer research and clinical oncology
researchProduct

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase…

2012

Purpose We report on a multicenter phase II trial of 90yttrium-ibritumomab-tiuxetan (90YIT) as first-line stand-alone therapy for patients with follicular lymphoma (FL). Patients and Methods Fifty-nine patients with CD20+ FL grade 1 to 3a in stages II, III, or IV, age 50 years old or older requiring therapy were enrolled. They received 90YIT according to standard procedure. If complete response (CR) or unconfirmed complete response (CRu) without evidence for minimal residual disease (MRD) 6 months after application of 90YIT was achieved, patients were observed without further intervention. The same applied to patients with partial response (PR) or with stable disease (SD). Patients with CR …

OncologyMaleCancer Researchmedicine.medical_specialtyPathologyNeoplasm ResidualTime FactorsFollicular lymphomaIbritumomab tiuxetanAntineoplastic AgentsDisease-Free SurvivalInternal medicinemedicineHumansLymphoma FollicularAgedNeoplasm StagingProportional Hazards ModelsAged 80 and overbusiness.industryFollow up studiesAntibodies MonoclonalMiddle AgedRadioimmunotherapymedicine.diseaseLymphomaFirst line treatmentClinical trialOncologyMulticenter studyNeoplasm stagingFemalebusinessmedicine.drugFollow-Up StudiesJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study.

2013

Human papillomavirus (HPV) is causally implicated in a subset of cancers of the upper aero-digestive tract (UADT). Methods Associations between type-specific HPV antibodies were examined among 1496 UADT cancer case subjects and 1425 control subjects by estimating odds ratios (ORs) in logistic regression analyses adjusted for potential confounders. The agreement between serology and tumor markers of HPV infection, including presence of HPV DNA and p16 expression, were examined in a subset of tumors. Results HPV16 L1 seropositivity was associated with increased risk of oral cavity and oropharyngeal cancer (OR = 1.94, 95% confidence interval [CI] = 1.03 to 3.65; OR = 8.60, 95% CI = 5.21 to 14.…

OncologyMaleCancer Researchmedicine.medical_specialtyvirusesPapillomavirus E7 ProteinsFluorescent Antibody TechniqueBiologyAntibodies ViralPolymerase Chain ReactionSerologyInternal medicinemedicineBiomarkers TumorOdds RatioHumansLaryngeal NeoplasmsAgedNeoplasm StagingHuman papillomavirus 16ConfoundingPapillomavirus InfectionsCase-control studyHPV infectionCancervirus diseasesOdds ratioOncogene Proteins ViralMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsUp-RegulationRepressor ProteinsOropharyngeal NeoplasmsOropharyngeal NeoplasmLogistic ModelsOncologyCase-Control StudiesImmunologyHuman papillomavirus 16; Oropharyngeal Neoplasms; Papillomavirus InfectionsDNA ViralEtiologyFemaleJournal of the National Cancer Institute
researchProduct

Prophylactic cranial irradiation in stage IV small cell lung cancer

2019

Background: Due to conflicting results between major trials the role of prophylactic cranial irradiation (PCI) in stage IV small cell lung cancer (SCLC) is controversial.Methods: We obtained a list of 13 European experts from both the European Society for Therapeutic Radiation Oncology (ESTRO) and the International Association for the Study of Lung Cancer (IASLC). The strategies in decision making for PCI in stage IV SCLC were collected. Decision trees were created representing these strategies. Analysis of consensus was performed with the objective consensus methodology.Results: The factors associated with the recommendation for the use of PCI included the fitness of the patient, young age…

OncologyMaleESTRO; Expert opinion; IASLC; PCI; Small cell lung cancer; Stage IV; Hematology; Oncology; Radiology Nuclear Medicine and ImagingLung Neoplasmsmedicine.medical_treatmentMedizin030218 nuclear medicine & medical imaging0302 clinical medicineQUALITY-OF-LIFENuclear Medicine and ImagingESTRO610 Medicine & healthStage IVHematologyBrain NeoplasmsRadiation OncologistsPCIHematologyMiddle AgedProgression-Free SurvivalExpert opinion030220 oncology & carcinogenesisFemaleTRIALNon small cellRadiologyAdultmedicine.medical_specialtyDecision Making03 medical and health sciencesInternal medicinemedicineHumansIASLCRadiology Nuclear Medicine and imagingLung cancerAgedNeoplasm StagingChemotherapySmall cell lung cancerbusiness.industryPatient Selectionmedicine.diseaseONCOLOGYSmall Cell Lung CarcinomaYoung ageConventional PCIProphylactic cranial irradiationCranial IrradiationbusinessStage ivRadiotherapy and Oncology
researchProduct

The evolutionary scenario of hepatocellular carcinoma in Italy: an update

2017

Background and aims Epidemiology of hepatocellular carcinoma is changing worldwide. This study aimed at evaluating the changing scenario of etiology, presentation, management and prognosis of hepatocellular carcinoma in Italy during the last 15 years. Methods Retrospective analysis of the ITA.LI.CA (Italian Liver Cancer) database including 5192 hepatocellular carcinoma patients managed in 24 centers from 2000 to 2014. Patients were divided into three groups according to the date of cancer diagnosis (2000-2004, 2005-2009 and 2010-2014). Results The main results were: 1) progressive patient aging; 2) progressive expansion of non-viral cases and, namely, of “metabolic” hepatocellular carcinoma…

OncologyMaleEtiologyDatabases FactualRadiofrequency ablationmedicine.medical_treatmentlaw.invention0302 clinical medicinelawEpidemiologyepidemiology; hepatocellular carcinoma; survival; treatment; HepatologyAged 80 and overSurveillancetreatmentLiver Neoplasmshepatocellular carcinomaMiddle AgedPrognosisItaly030220 oncology & carcinogenesisHepatocellular carcinomaCatheter Ablation030211 gastroenterology & hepatologyFemaleepidemiology; hepatocellular carcinoma; survival; treatmentepidemiologyalpha-FetoproteinsLiver cancerAdultmedicine.medical_specialtyCarcinoma Hepatocellularsurvival03 medical and health sciencesYoung AdultAge DistributionInternal medicinemedicineHumansSex DistributionAgedNeoplasm StagingRetrospective StudiesCirrhosiHepatologybusiness.industryCancer stageSettore MED/09 - MEDICINA INTERNACancermedicine.diseaseSurgeryepidemiology; hepatocellular carcinoma; survival; treatment; Adult; Age Distribution; Aged; Aged 80 and over; Carcinoma Hepatocellular; Catheter Ablation; Databases Factual; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sex Distribution; Young Adult; alpha-FetoproteinsEtiologyPercutaneous ethanol injectionbusiness
researchProduct

A Tetra-Panel of Serum Circulating miRNAs for the Diagnosis of the Four Most Prevalent Tumor Types

2020

The purpose of this study is to clinically validate a series of circulating miRNAs that distinguish between the 4 most prevalent tumor types (lung cancer (LC)

OncologyMaleLung NeoplasmsColorectal cancerlcsh:ChemistryProstate cancer0302 clinical medicinelcsh:QH301-705.5SpectroscopyEarly Detection of CancerAged 80 and over0303 health sciencesArea under the curveGeneral MedicineMiddle AgedEarly diagnosisprostate cancer3. Good healthComputer Science Applications030220 oncology & carcinogenesisArea Under CurveFemaleColorectal NeoplasmsAdultmedicine.medical_specialtyBreast Neoplasmscolorectal cancerCatalysisArticleInorganic Chemistry03 medical and health sciencesBreast cancerbreast cancerInternal medicinemedicineHumansCirculating MicroRNAPhysical and Theoretical ChemistryLung cancerMolecular Biology030304 developmental biologyAgedNeoplasm StagingReceiver operating characteristicbusiness.industryOrganic ChemistryCancerProstatic Neoplasmsmedicine.diseaseCirculating MicroRNAlung cancerlcsh:Biology (General)lcsh:QD1-999ROC CurveCase-Control StudiesMultivariate Analysiscirculating microRNAsbusinessInternational Journal of Molecular Sciences
researchProduct

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).

2019

Recently, immunotherapy has been shown to be an effective and helpful therapeutic option for the treatment of advanced non-small-cell lung cancer (NSCLC). The activity of antitumor T cells may be restored through the checkpoint blockade using anti-programmed death 1 or anti-programmed death ligand 1 (PD-L1) antibodies, showing, in several cancer patients, an increased progression-free survival and overall survival compared with classical chemotherapy. As recently shown by several studies, the PD-L1 expression levels in tumors may offer a selection criterion for patients to predict their immunotherapy response. In particular, NSCLC patients with high tumor PD-L1 levels (proportional score ≥ …

OncologyMalePD-L1030213 general clinical medicinemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentT-LymphocytesProgrammed Cell Death 1 Receptornon-small cell lung cancer (NSCLC)PembrolizumabReviewAntibodies Monoclonal HumanizedNSCLCB7-H1 Antigen03 medical and health sciences0302 clinical medicineAntineoplastic Agents ImmunologicalCheckpoint inhibitorPD-L1Internal medicineCarcinoma Non-Small-Cell LungPD-1medicineHumansPharmacology (medical)Molecular Targeted TherapyLung cancerNeoplasm StagingChemotherapybiologybusiness.industryCancerGeneral MedicineImmunotherapymedicine.diseasePrognosisImmunohistochemistrySurvival AnalysisPredictive biomarker030220 oncology & carcinogenesisbiology.proteinBiomarker (medicine)Lung cancerbusinessPembrolizumabBiomarkersCheckpoint inhibitorsAdvances in therapy
researchProduct